Skip to main
CRBP
CRBP logo

CRBP Stock Forecast & Price Target

CRBP Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corbus Pharmaceuticals Holdings Inc. is positioned favorably in the precision oncology sector, driven by promising developments in its pipeline, particularly CRB-701 and CRB-601. The recent presentation of updated data at ASCO GU 2025 indicates a compelling 44% overall response rate for CRB-701, highlighting its potential in both efficacy and safety compared to existing ADCs like Tivdak, without significant dose-limiting toxicities. Additionally, the ongoing development of CRB-601, which targets αvβ8 integrins to inhibit the activation of latent TGFβ, enhances the company's portfolio appeal, suggesting robust growth prospects as these therapies advance through clinical evaluation.

Bears say

Corbus Pharmaceuticals Holdings Inc. faces significant challenges that contribute to a negative outlook on its stock, primarily driven by the risk of regulatory approval delays and clinical trial failures related to its drug candidates, including CRB-913 and CRB-601. These factors, combined with concerns over the competitive landscape influenced by Novo Nordisk's new obesity treatments, suggest that the current valuation may be overly optimistic and not justified by the company's pipeline. Furthermore, complications such as ocular toxicity associated with Tivdak may hinder market adoption and impede revenue generation, further exacerbating the company's financial uncertainties.

CRBP has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corbus Pharmaceuticals Holdings (CRBP) Forecast

Analysts have given CRBP a Buy based on their latest research and market trends.

According to 13 analysts, CRBP has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corbus Pharmaceuticals Holdings (CRBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.